Treatment of dyslipidaemia in high-risk patients: Too little, too late

International Journal of Clinical Practice, Supplement

Volumn , Issue 130, 2002, Pages 15-19

  Barter, P ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATINE DERIVATIVE;

CLINICAL TRIAL; CONFERENCE PAPER; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; NIACIN;

EID: 0036636089     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial
2. Cholesterol and mortality. 30 Years of follow-up from the Framingham Study
3. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
4. The Münster Heart Study (PROCAM). Results of follow-up at 8 years
5. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
11. Joint effects of serum triglyceride and LDL cholesterol and HDL-C concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
12. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
13. Secondary prevention by raising HDL-C and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
14. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
15. Regression of atherosclerosis lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit
16. Prevention of coronary heart disease in clinical practice
17. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
18. A European Society of Cardiology Survey of Secondary Prevention of coronary heart disease. European action on secondary prevention through intervention to therapeutic events. Principal results
19. Primary prevention of coronary heart disease in women through diet and lifestyle
20. Prospective study of major dietary patterns and risk of coronary heart disease in men
21. A meta-analysis of physical activity in the prevention of coronary heart disease
22. Physical activity and 10.5 year mortality in the Multiple Risk Factor Intervention Trial (MRFIT)
23. Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate